• Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Included in NIH-Sponsored Phase 3 Clinical Trial of Hyperimmune Intravenous Immunoglobulin to Treat COVID-19

    Источник: Nasdaq GlobeNewswire / 08 окт 2020 13:05:10   America/Los_Angeles

    N/A
Опубликовать